drugset / Trial / NCT00464087
Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this clinical trial is to evaluate safety of switching from fondaparinux to either unfractionated heparin or bivalirudin for patients experiencing acute coronary syndrome undergoing percutaneous coronary angioplasty.
Timeline
- Start
- 2007-06
- Primary completion
- 2010-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bivalirudin | Peptide | 1.75 unknown | Intravenous |
| Comparator | Heparin | Other / unclassified | 60 iu/kg | Intravenous |
| Comparator | Fondaparinux | Other / unclassified | — | — |